12:00 AM
Feb 25, 2013
 |  BC Week In Review  |  Clinical News  |  Regulatory

Hexyon/Hexacima regulatory update

EMA's CHMP issued a positive opinion recommending approval of an MAA for Hexyon/Hexacima from Sanofi for primary and booster vaccination against diphtheria, tetanus, pertussis, Hepatitis B, polio and Haemophilus influenzae type b (Hib) in infants and toddlers ages 6 weeks to 24 months....

Read the full 195 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >